<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01454856</url>
  </required_header>
  <id_info>
    <org_study_id>2011/30MAI/218</org_study_id>
    <nct_id>NCT01454856</nct_id>
  </id_info>
  <brief_title>Perioperative Evaluation of Immuno-inflammatory Parameters</brief_title>
  <official_title>Perioperative Evaluation of Immuno-inflammatory Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study consists of evaluations, using blood tests, various immune, inflammatory and
      coagulation parameters in the perioperative settings (different substudies), without changing
      anything to what is expected.

      This will allow us to clarify the possible impact of surgery and analgesia on perioperative
      activation of these pathways.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A significant number of published data can be concluded that surgery and anesthetic and
      analgesic techniques have an impact on immunity and inflammation.

      However, none of these studies have been performed with modern techniques, much more reliable
      evaluation of immune activity, such as the assessment of monocytic degranulation by flow
      cytometry.

      It is therefore important to document immune activity using these new techniques, our
      patients, perioperative. This will be analyzed, so observational, the potential impact of
      different therapeutic interventions the patient receives.

      This study consists of evaluations, using blood tests, various immune, inflammatory and
      coagulation parameters in the perioperative settings (different substudies), without changing
      anything to what is expected.

      This will allow us to clarify the possible impact of surgery and analgesia on perioperative
      activation of these pathways.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immune parameters (immunocytes phenotype)</measure>
    <time_frame>baseline up to 8 days (return to baseline)</time_frame>
    <description>Function tests and surface markers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long term outcome</measure>
    <time_frame>5 years</time_frame>
    <description>General morbidity and mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation parameters (like platelet function) (substudy)</measure>
    <time_frame>perioperative period (up to 3 days)</time_frame>
    <description>Function tests and surface markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers (cytokines) (substudy)</measure>
    <time_frame>baseline up to 8 days (return to baseline)</time_frame>
    <description>Intracellular FACS and ELISA measures</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Combined Inflammatory and Immunologic Defect</condition>
  <arm_group>
    <arm_group_label>Surgical cancer patients</arm_group_label>
    <description>No modification of the treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-surgical cancer patients</arm_group_label>
    <description>No modification of the treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgical non-cancer patients</arm_group_label>
    <description>No modification of the treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-surgical non-cancer patients</arm_group_label>
    <description>No modification of the treatment</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and cells (PBMCs) frozen in cryotubes
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort of patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Surgical patients (and controls)

        Exclusion Criteria:

          -  Immune disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrice Forget, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2011</study_first_submitted>
  <study_first_submitted_qc>October 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2011</study_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université Catholique de Louvain</investigator_affiliation>
    <investigator_full_name>Forget Patrice</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

